Skip to main content

NexoBrid FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 17, 2023.

FDA Approved: Yes (First approved December 28, 2022)
Brand name: NexoBrid
Generic name: anacaulase-bcdb
Dosage form: for Topical Gel
Company: MediWound Ltd.
Treatment for: Thermal Burn

NexoBrid (anacaulase-bcdb) is a concentrate of proteolytic enzymes indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.



Development timeline for NexoBrid

Dec 29, 2022Approval FDA Approves NexoBrid (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.